Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iLCA

Financiado

Cerrado

Intelligent Live Cell Analysis iLCA to transform disease management through fa...

Intelligent Live Cell Analysis iLCA to transform disease management through faster and more regulatory robust discovery manufacture and monitoring of biologic drugs cell therapies The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in autom... ver más

31/07/2021

VALITACELL LTD

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

VALITACELL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

VALITACELL LTD

1.14M€ | Lider

TAVIL-INDEBE

200.35K€ | Participante

Solentim Ltd

708.42K€ | Participante

MICRO

594.45K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

II-LCA Integrated Imaging in live Cell Analysis II LCA for enhan... 124K€ Cerrado

Cellphmed Accurate cell signatures for the advancement of personalized... 150K€ Cerrado

STEM-TECH STEM TECH Introducing proprietary stem cell marker technolo... 163K€ Cerrado

PTQ2021-012177 Desarrollo de la primera plataforma tecnológica de ensayos a... 55K€ Cerrado

BURnOUT Enabling efficient cell engineering leaving gene-expression... 150K€ Cerrado

ENLIGHT-TEN European Network linking informatics and genomics of helper... 3M€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2019-05-15
Fecha Fin: 2021-07-31

Líder del proyecto

VALITACELL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire life‐cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores